As experts dedicated to providing patients with compassionate, evidence-based care every day, we are disappointed in the United States v. Skrmetti decision, which increases the likelihood that other states will limit or eliminate families’ and patients’ ability to access medical care. As doctors, nurse practitioners, and nurses, we believe that every patient is different. Decisions...
AMA Passes Resolution Calling for Expanded Access to Anti-obesity Medications
Endocrine Society champions resolution passed by House of Delegates On June 10, the American Medical Association (AMA) House of Delegates passed the Endocrine Society’s resolution to improve access to anti-obesity medications. In the resolution, the AMA committed to advocating for reducing the burden of prior authorization, when healthcare providers must seek insurance plan approval before...
The Endocrine Society today endorsed the introduction of the bipartisan Treat and Reduce Obesity Act (TROA) in the Senate. The legislation will ensure that Medicare and Medicaid beneficiaries have access to effective anti-obesity medications. Medicare coverage of anti-obesity medications is currently prohibited under law. Access to these medications would benefit millions of Americans. More than...
The Endocrine Society has selected Yoshitomo Hoshino, MD, PhD, as the recipient of its 2025 C. Wayne Bardin, MD, International Travel Award for his outstanding ENDO abstract and research contributions to the care of patients with bone health disorders. The C. Wayne Bardin, MD, International Travel Award was created in honor of Past President Wayne...
The Endocrine Society has appointed Manuel Tena-Sempere, MD, PhD, of the University of Cordoba in Spain, as the next editor-in-chief of its flagship basic science journal, Endocrinology, starting January 2026. Manuel Tena-Sempere is a professor of physiology at the University of Cordoba, a research group leader at the biomedical research institute of Cordoba (IMIBIC) and...
The Endocrine Society is extremely disappointed the administration has chosen not to finalize a rule that would have made anti-obesity medications more accessible to millions of Americans with obesity. The administration decided not to implement a proposal that would have allowed Medicare and Medicaid to cover anti-obesity medications for weight loss. Many Medicare and Medicaid...
Endocrine Society Statement on HHS Restructuring, Mass Firings, and Scientific Review
A major reorganization of the U.S. Department of Health and Human Services (HHS) — including massive cuts to the federal workforce — threatens scientific progress that drives our economy and improves the public’s health. Slashing federal funding and staff will hobble the very agencies that fuel medical discoveries and approve new treatments. In addition, the...
Endocrine Society Calls for Restoration of Diabetes Prevention Program
Three decades of landmark research into type 2 diabetes prevention abruptly ended this month due to government funding cuts. The Endocrine Society calls on the administration to restore the Diabetes Prevention Program (DPP) and DPP Outcomes Study funded through the National Institutes of Health. The Society is concerned about how the loss of this ongoing...
